TOKYO and NEW YORK, Dec 23, 2021 — CMIC Co., Ltd. (“CMIC”), the first and largest Japanese contract research organization (CRO), and Lokavant, a leading clinical trial intelligence company, today announced that they have significantly expanded their enterprise partnership.
After a successful initial engagement in which Lokavant structured and harmonized operational data across hundreds of historical trials, benchmarked CMIC operational performance across the enterprise, and deployed Oversight, its real-time operational analytics application, CMIC will now leverage Lokavant’s data harmonization and predictive analytics capabilities across CMIC’s ongoing and future trials.
CMIC is the largest clinical service provider in the Asia-Pacific (APAC) region, with over 28 years of pharmaceutical development experience. More than 80% of new drug development in Japan is supported by the CMIC Group. The initial 6-month phase of CMIC’s partnership with Lokavant represents the largest data and analytics partnership in the region, strengthening CMIC’s leadership position.
The new, multi-year partnership puts Lokavant’s platform at the core of CMIC’s technology and innovation strategy and continues to expand Lokavant’s growing presence in APAC. As part of the enterprise agreement, Lokavant will:
● Ingest and harmonize all operational data from ongoing and future studies, building upon what is already the largest operational data repository in the APAC region. CMIC will use Lokavant’s platform as its single source of truth for data across their trials.
● Leverage these data along with Lokavant’s proprietary data asset, comprised of de-identified, historical data from thousands of trials, to power Lokavant’s analytical engine. This will allow CMIC to measure and improve their trial execution performance with predictive insights.
● Deploy Oversight at the enterprise level across CMIC’s team of >1,200 clinical operators. This next-generation risk-based monitoring application will enable CMIC’s teams to take proactive action mitigating risks and maintaining compliance with ICH guidelines, to ensure more efficient, higher quality trials.
● Rapidly deploy analytics applications beyond risk-based monitoring to better support sponsor, CRO, site, and participant data transparency and connectivity.
“Like most drug development companies in our region, our data were previously siloed across different teams, source systems, and studies. In just a few weeks, Lokavant was able to connect and harmonize operational data across hundreds of studies and uncover insights about our performance that we had never seen before,” said Yoshihito Kondo, Executive Vice President of Clinical Operations at CMIC. “These insights have already helped drive a step-change in performance across our enterprise, and enable better time, cost, and quality outcomes for sponsors here in APAC. We are excited to expand our strategic partnership and to make Lokavant our clinical trial intelligence solution across all future trials. As the APAC market continues to grow, this partnership will help solidify CMIC’s leadership position, driving better, data-driven clinical operations to the region and delivering critical therapies to patients in need.”
“CMIC has been an excellent partner, and we are excited to expand our collaboration across additional studies and new data-driven applications,” said Rohit Nambisan, President of Lokavant. “This expansion represents further validation for leveraging clinical intelligence across all trials and trial stakeholders. It is our expectation that the combination of our technology and CMIC’s experience in the region will significantly improve both trial efficiency and outcomes in APAC, a key market with high unmet medical needs.”
Lokavant is a clinical intelligence platform that improves the time, cost, and quality of trial execution through data-driven analytics applications. Lokavant’s platform aggregates and integrates real-time data from disparate trial data sources, powers analytics to allow study teams to proactively manage their studies, and surfaces insights in intuitive applications, driving all scientific and operational use cases.
About CMIC Group
CMIC Group was founded in 1992 as the first Contract Research Organization (CRO) in Japan. Today CMIC Group is the largest clinical CRO in Japan with a global footprint, providing comprehensive services in drug development, clinical site management, manufacturing, regulatory consulting and contract sales & marketing solutions. We can help pharmaceutical, biotech and medical device companies to enter the Japanese market, to conduct clinical trials in Asia, or to bridge drug development and manufacturing needs in the US, Europe, Japan and broader Asia. CMIC Group has over 7,000 employees and 24 sites globally. For more information about CMIC Group and services, please visit our website. https://en.cmicgroup.com/
CMIC HOLDINGS Co., LTD.